TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04457011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Susu Xiao'er Zhike Granules 1 bag
Description: High dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 20.25 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Middle dose Susu Xiao'er Zhike Granules 1 bag
Description: Middle dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 10.12 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Extremely-low dose Susu Xiao'er Zhike Granules 1 bag
Description: Extremely-low dose Susu Xiao'er Zhike Granules 1 bag(9g granule per bag,contains 1.01 g crude herbs), twice a day (7-9a.m. and 5-7p.m.) for five days
Study: NCT01874522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102 tablets
Description: Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.~Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102 oral solution
Description: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout
Study: NCT03713437

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of differentially methylated insulin DNA
Description: A serum sample will be drawn to measure differentially methylated insulin DNA.

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of differentially methylated insulin DNA
Description: A serum sample will be drawn to measure differentially methylated insulin DNA.
Study: NCT03578276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate 1% ophthalmic suspension
Description: Steroidal anti-inflammatory
Study: NCT03925402

Intervention type: DRUG
Intervention: Ertapenem
Description: Ertapenem injection

Intervention type: DRUG
Intervention: Carbapenems
Description: Other carbapenems injection
Study: NCT03578276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gatifloxacin Ophthalmic
Description: Antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac 0.075% Oph Solution
Description: Non-steroidal anti-inflammatory
Study: NCT03413865

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visits conducted via Telemedicine
Description: Patients will be followed via telemedicine with visits lead by a Pharmacist and a Nurse
Study: NCT01077115

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Surgery
Study: NCT01901315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Online consultation
Description: Patients in the online consultation (intervention) group have monthly consultation with their attending psychiatrist through videoconferencing during one year. After each consultation, the medication is sent to the patient through a home delivery program. For reasons of patient safety, consultations at baseline, and after 6 and 12 months will be realized in a face-to-face form at the Institute of Psychiatry (IPq).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Face-to-face consultation
Description: Patients in the face-to-face consultation (control) group have monthly face-to-face consultation with their attending psychiatrist during one year at the Institute of Psychiatry (IPq).
Study: NCT03874806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25%-NaCl 0.9% Injectable Solution
Description: 0.25% ropivacaine administered through a nerve catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.2%-NaCl 0.9% Injectable Solution
Description: 0.2% ropivacaine administered through a nerve catheter
Study: NCT03342508

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fetal Pillow
Description: see arm description
Study: NCT04246190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-501 and D759
Description: Reference drug, CKD-501 1T and D759 1T, QD, PO
Study: NCT03972813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Broadened information about cancers
Description: Caregivers receive information that HPV causes more than just cervical cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Broadened information about cancers
Description: Caregivers receive information that HPV causes more than just cervical cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Broadened information about cancers
Description: Caregivers receive information that HPV causes more than just cervical cancer.
Study: NCT04246190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-396
Description: Reference drug, CKD-396 1T, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-396
Description: Reference drug, CKD-396 1T, QD, PO
Study: NCT02595333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group SF1
Description: primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group S1
Description: sufentanil was administered for analgesia in primary cesarean section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group SF2
Description: sufentanil and flurbiprofen was administered for analgesia in repeated cesarean section

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group S2
Description: sufentanil was administered for analgesia in repeated cesarean section
Study: NCT01365845

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon
Description: 50.4 Gy to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-Proton/Conventional plan or 3D-proton only
Description: 50.4 Cobalt Gray Equivalent/Gray to the breast/chest wall and peripheral lymph nodes at 1.8 Cobalt Gray Equivalent/Gray per fraction
Study: NCT01712230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: Drug: leuprolide acetate~Other Names:~Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: Drug: leuprolide acetate~Other Names:~Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months
Study: NCT04599088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain functional MRI with simplified urodynamics
Description: Structural:~MPRAGE provides a structural image, which is used for coregistration of subjects. Structural scans are then performed including Diffusion Spectrum Imaging (DSI; microstructural), and Fluid-attenuated inversion recovery (FLAIR; white matter specific) scans.~Functional:~With about 50 ml in the bladder, resting state functional BOLD measurements are made, followed by functional whole-brain images while a small amount of saline is infused and withdrawn from the bladder, in 2 blocks of 4 repetitions each. Each repetition starts with a 12-scan pause, followed by infusion (6 scans = 12 s), pause (6 scans), and withdrawal (6 scans). Each block of 4 repetitions is completed by a 6 scan pause during which scanning continues. 24 ml is infused at 120 ml/min, and slightly less is withdrawn to avoid accommodation.This is repeated on an empty and full bladder along with a resting state image.
Study: NCT03800134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg on Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and 1500mg on Day 1 of each 4-week cycle for 12 cycles during the adjuvant period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Day 1 of each 3-week cycle for 4 cycles during the neoadjuvant period and Day 1 of each 4-week cycle for 12 cycles during the adjuvant period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the curve of 5/6 on Day 1 of each 3-week cycle for 4 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Area under the curve of 5/6 on Day 1 of each 3-week cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 on Day 1 of each 3-week cycle, for 4 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2 on Day 1 of each 3-week cycle, for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 on Day 1 of each 3-week cycle for 4 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m2 on Day 1 of each 3-week cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200mg/m2 on Day 1 of each 3-week cycle for 4 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 200mg/m2 on Day 1 of each 3-week cycle for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: 1250 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for 4 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Expected within 40 days from the last dose of Investigational Product following the completion of neoadjuvant treatment.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: Expected within 40 days from the last dose of Investigational Product following the completion of neoadjuvant treatment.
Study: NCT04690738

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal Elastase Concentration
Description: Stool sample for fecal elastase-1 (FEC) analysis and microbiome for sequencing and analysis will be obtained pre- and post-transplant.
Study: NCT04739956

Intervention type: OTHER
Intervention: The Hospital and Anxiety Depression Scale
Description: Patients and partners will be asked to complete the questionnaire at three time points: 1) On classification of PUL at time zero once blood is taken, 2) at the 48-hour time point after blood is taken (if 48 hour bloods are required for the patient); and 3) after definitive diagnosis and management.

Intervention type: OTHER
Intervention: The Hospital and Anxiety Depression Scale
Description: Patients and partners will be asked to complete the questionnaire at three time points: 1) On classification of PUL at time zero once blood is taken, 2) at the 48-hour time point after blood is taken (if 48 hour bloods are required for the patient); and 3) after definitive diagnosis and management.

Intervention type: OTHER
Intervention: Point of care testing (POCT)
Description: Patients will have 1ml sample of blood taken for POCT at two time points: 1) On classification of PUL at time zero at the same time as when routine blood samples taken; and 2) at the 48-hour time point at the same time as when routine blood samples are taken (if 48 hour bloods are required).

Intervention type: OTHER
Intervention: Point of care testing (POCT)
Description: Patients will have 1ml sample of blood taken for POCT at two time points: 1) On classification of PUL at time zero at the same time as when routine blood samples taken; and 2) at the 48-hour time point at the same time as when routine blood samples are taken (if 48 hour bloods are required).
Study: NCT03270020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab 70 MG/ML [Xgeva]
Description: As already described in arm description
Study: NCT00747149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral
Study: NCT04528147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yi Jin Jing Tiger Roaring Speech Rehabilitation
Description: A traditional Chinese medicine treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Speech Rehabilitation
Description: A active speech rehabilitation method recommended by the Parkinson's Foundation of America
Study: NCT04105764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: DEEP block to PTC 1-3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium bromide
Description: MODERATE block to TOF1-2
Study: NCT01712230

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised cardiovascular exercise
Description: Supervised exercise, 4 days per week for 45 to 60 minutes per session for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03196180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Given intravaginally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Fluorouracil
Description: Given intravaginally
Study: NCT01360606

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT:~Patients will receive one of the following radiation regimens:~* 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.~* 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.~* 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period.
Study: NCT05079789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Treatment with amiloride, start dose 5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Treatment with furosemide, start dose 40 mg
Study: NCT03483246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Description: The colonoscopy for FMT will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then receive either FMT (frozen preparation of 50g of stools in 300ml of physio, see donor section for details) or sham transplantation (FMT vehicle) in the cecum.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham-transplantation Placebo
Description: The sham-transplantation will be planned as soon as possible and never more than 5 weeks after inclusion visit.~After colon cleansing using Polyethylen glycol, the patient will have a colonoscopy under general anesthesia.~The patient will then sham transplantation (FMT vehicle) in the cecum.
Study: NCT04288726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD30.CAR-EBVST cells
Description: The dose is based on the number of CD30.CAR-expressing cells. In our previous study the highest dose was 2 × 10\^8 cells/m2 and we did not reach an MTD. This will be administered as a single infusion of the full dose for each level, which was already shown to be safe in the first 3 patients treated at dose level 3. Since we have not observed any dose limiting toxicities at the current dose level (Dose Level 3 as of June 2022), we propose to include a new higher dose level (8 × 10\^8).There will be a gap of 4 weeks between the first and second patient, and between the second and the third patient, on each dose level.
Study: NCT04296383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin plus Xiyanping injection
Description: Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d;Xiyanping injection intravenously, 0.4mL / (kg.d) daily, Qd

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin for injection is 10mg / (kg • d), the maximum dose does not exceed 0.5g / d
Study: NCT04063566

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Prostate cancer screening MRI

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Prostate-specific antigen (PSA) test
Description: Blood test for PSA levels
Study: NCT01534975

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: contrast agent
Description: we are randomizing patients to different contrast agents.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: contrast agent
Description: we are randomizing patients to different contrast agents.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: contrast agent
Description: we are randomizing patients to different contrast agents.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: contrast agent
Description: we are randomizing patients to different contrast agents.
Study: NCT04800445

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary CRP
Description: Salivary C reactive protein in neonatal sepsis

Intervention type: DIAGNOSTIC_TEST
Intervention: Salivary CRP
Description: Salivary C reactive protein in neonatal sepsis
Study: NCT01548950

Intervention type: DRUG
Group type: OTHER
Intervention: Sildenafil singly or in association with Bosentan
Description: Sildenafil, 1-4 mg/Kg/day (6-hour intervals) preoperatively, until development of pulmonary congestion (generally 1-4 weeks) or preoperatively, for 10-12 months, in association with bosentan (15.6-62.5 mg b.i.d.) if pulmonary congestion does not develop. Surgery will be performed at 1-4 weeks (short-term treatment) or at 10-12 months (medium-term treatment) if operability criteria are met (catheterization). In both cases (short and medium-term treatments), the drug or drugs will be kept for 6 months postoperatively, when final catheterization will be performed for efficacy testing.
Study: NCT01504828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Ramipril in one dose to reduce vascular stiffness to determine effects of this on left ventricular function and energetics
Study: NCT00468923

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Candesartan/HCT
Description: Candesartan 16 mg/HCT 12.5 once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 10 mg once daily
Study: NCT02351128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Study: NCT00270699

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN4delta30-200,201
Description: Live attenuated dengue 4 vaccine (one of three doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN4delta30-200,201
Description: Live attenuated dengue 4 vaccine (one of three doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN4delta30-200,201
Description: Live attenuated dengue 4 vaccine (one of three doses)
Study: NCT03916237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral to Medical Legal Partnership
Description: Medical Legal Partnership referral as described by the National Center for Medical Legal partnerships and others (Beck AF, Identifying and treating a substandard housing cluster using a medical-legal partnership. Pediatrics. 2012;130(5):831-838)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular School Based Health Asthma Care
Description: Regular care in the School Health Program
Study: NCT00270699

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rDEN4delta30-200,201
Study: NCT04639687

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food as Medicine Delivery
Description: 12 consecutive weeks of home-delivered vegetables plus whole grain foods along with weekly text containing educational video

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Food as Medicine Delivery
Description: 12 consecutive weeks of home-delivered vegetables plus whole grain foods along with weekly text containing educational video
Study: NCT04592991

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of 64Cu-DOTA-ECL1i
Description: Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with non-aneurysmal, atherosclerotic aortoiliac occlusive disease (n=3) will be enrolled in Aim 2A and undergo Cu-64 DOTA-ECL1i PET/CT.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: AAA Group- PET-CT imaging with injection of 64Cu-DOTA-ECL1i
Description: Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with Abdominal aortic aneurysm (AAA) (n=5) will be enrolled in Aim 2B and undergo Cu-64 DOTA-ECL1i PET/CT and contrast-enhanced CT angiography between 7-14 days of their scheduled elective open repair surgery.
Study: NCT03564899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lighter intensity physical activity intervention
Description: Prescription of 300 minutes/week of physical activity at an intensity of 40-60% of heart rate reserve

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Higher intensity physical activity intervention
Description: Prescription of 150 minutes/week of physical activity at an intensity of 60-80% of heart rate reserve
Study: NCT01033864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: 1 g per day b.i.d. p.o. for at least 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC-MPS
Description: 720 mg b.i.d. p.o. for at least 1 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg per day p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg per day p.o.
Study: NCT01862328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: MLN4924 (intravenously \[IV\]) in participants in a 21-day cycle:~* MLN4924 on Days 1,3,5 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: MLN4924 (intravenously \[IV\]) in participants in a 21-day cycle:~* MLN4924 on Days 1,3,5 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN4924
Description: MLN4924 (intravenously \[IV\]) in participants in a 21-day cycle:~* MLN4924 on Days 1,3,5 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (IV) in a 21-day cycle:~* Paclitaxel on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (IV) in participants in a 28-day cycle:~-Gemcitabine on Days 1,8,15 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (IV) in participants in a 21-day cycle:~- Docetaxel on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (IV) in participants in a 21-day cycle:~- Carboplatin on Day 1 of each cycle
Study: NCT02889328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib 100mg continuous dosing arm